Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective Article Swipe
Matthew Lei
,
Qianyi Li
,
Ken O’Day
,
Kellie Meyer
,
Anthony Wang
,
Monika Jun
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1080/14796694.2024.2354157
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1080/14796694.2024.2354157
Aim: Novel treatment options for relapsed/refractory diffuse large B-cell lymphoma include T-cell targeting therapies. Practice efficiency and cost are important for informed treatment decisions.Materials/methods: An institutional decision-maker cost model was developed for 6-month, 1-year and median cycles of treatment time horizons comparing practice efficiency and costs of epcoritamab vs glofitamab and axicabtagene ciloleucel (axi-cel).Results: Overall, epcoritamab required the shortest personnel and chair time, except over 1 year (second shortest chair time). Across all time horizons, epcoritamab was cost-saving vs axi-cel and had similar costs to glofitamab on a per-month basis.Conclusion: Epcoritamab reduced personnel and chair time. Additionally, epcoritamab was cost-saving vs axi-cel and had similar costs to glofitamab on a per-month basis.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1080/14796694.2024.2354157
- OA Status
- green
- References
- 32
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4399943252
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4399943252Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1080/14796694.2024.2354157Digital Object Identifier
- Title
-
Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspectiveWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-06-24Full publication date if available
- Authors
-
Matthew Lei, Qianyi Li, Ken O’Day, Kellie Meyer, Anthony Wang, Monika JunList of authors in order
- Landing page
-
https://doi.org/10.1080/14796694.2024.2354157Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/11508956Direct OA link when available
- Concepts
-
Medicine, Total cost, Clinical Practice, Refractory (planetary science), Perspective (graphical), Lymphoma, Cost efficiency, Cost–benefit analysis, Oncology, Internal medicine, Family medicine, Accounting, Computer science, Business, Ecology, Astrobiology, Physics, Biology, Artificial intelligence, Operating systemTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
32Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4399943252 |
|---|---|
| doi | https://doi.org/10.1080/14796694.2024.2354157 |
| ids.doi | https://doi.org/10.1080/14796694.2024.2354157 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38913826 |
| ids.openalex | https://openalex.org/W4399943252 |
| fwci | 0.0 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000628 |
| mesh[1].descriptor_ui | D016403 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapy |
| mesh[1].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[2].qualifier_ui | Q000191 |
| mesh[2].descriptor_ui | D016403 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | economics |
| mesh[2].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[3].qualifier_ui | Q000188 |
| mesh[3].descriptor_ui | D016403 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | drug therapy |
| mesh[3].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[4].qualifier_ui | Q000191 |
| mesh[4].descriptor_ui | D016219 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | economics |
| mesh[4].descriptor_name | Immunotherapy, Adoptive |
| mesh[5].qualifier_ui | Q000379 |
| mesh[5].descriptor_ui | D016219 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | methods |
| mesh[5].descriptor_name | Immunotherapy, Adoptive |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D003362 |
| mesh[6].is_major_topic | True |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Cost-Benefit Analysis |
| mesh[7].qualifier_ui | Q000191 |
| mesh[7].descriptor_ui | D018033 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | economics |
| mesh[7].descriptor_name | Antibodies, Bispecific |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D018033 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Antibodies, Bispecific |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D000076962 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Receptors, Chimeric Antigen |
| mesh[10].qualifier_ui | Q000628 |
| mesh[10].descriptor_ui | D009364 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | therapy |
| mesh[10].descriptor_name | Neoplasm Recurrence, Local |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D001688 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Biological Products |
| mesh[12].qualifier_ui | Q000191 |
| mesh[12].descriptor_ui | D001688 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | economics |
| mesh[12].descriptor_name | Biological Products |
| mesh[13].qualifier_ui | Q000706 |
| mesh[13].descriptor_ui | D017048 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | statistics & numerical data |
| mesh[13].descriptor_name | Health Care Costs |
| mesh[14].qualifier_ui | |
| mesh[14].descriptor_ui | D006801 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | |
| mesh[14].descriptor_name | Humans |
| mesh[15].qualifier_ui | Q000628 |
| mesh[15].descriptor_ui | D016403 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapy |
| mesh[15].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[16].qualifier_ui | Q000191 |
| mesh[16].descriptor_ui | D016403 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | economics |
| mesh[16].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D016403 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[18].qualifier_ui | Q000191 |
| mesh[18].descriptor_ui | D016219 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | economics |
| mesh[18].descriptor_name | Immunotherapy, Adoptive |
| mesh[19].qualifier_ui | Q000379 |
| mesh[19].descriptor_ui | D016219 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | methods |
| mesh[19].descriptor_name | Immunotherapy, Adoptive |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D003362 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Cost-Benefit Analysis |
| mesh[21].qualifier_ui | Q000191 |
| mesh[21].descriptor_ui | D018033 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | economics |
| mesh[21].descriptor_name | Antibodies, Bispecific |
| mesh[22].qualifier_ui | Q000627 |
| mesh[22].descriptor_ui | D018033 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | therapeutic use |
| mesh[22].descriptor_name | Antibodies, Bispecific |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D000076962 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Receptors, Chimeric Antigen |
| mesh[24].qualifier_ui | Q000628 |
| mesh[24].descriptor_ui | D009364 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | therapy |
| mesh[24].descriptor_name | Neoplasm Recurrence, Local |
| mesh[25].qualifier_ui | Q000627 |
| mesh[25].descriptor_ui | D001688 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | therapeutic use |
| mesh[25].descriptor_name | Biological Products |
| mesh[26].qualifier_ui | Q000191 |
| mesh[26].descriptor_ui | D001688 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | economics |
| mesh[26].descriptor_name | Biological Products |
| mesh[27].qualifier_ui | Q000706 |
| mesh[27].descriptor_ui | D017048 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | statistics & numerical data |
| mesh[27].descriptor_name | Health Care Costs |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D006801 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Humans |
| mesh[29].qualifier_ui | Q000628 |
| mesh[29].descriptor_ui | D016403 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | therapy |
| mesh[29].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[30].qualifier_ui | Q000191 |
| mesh[30].descriptor_ui | D016403 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | economics |
| mesh[30].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[31].qualifier_ui | Q000188 |
| mesh[31].descriptor_ui | D016403 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | drug therapy |
| mesh[31].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[32].qualifier_ui | Q000191 |
| mesh[32].descriptor_ui | D016219 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | economics |
| mesh[32].descriptor_name | Immunotherapy, Adoptive |
| mesh[33].qualifier_ui | Q000379 |
| mesh[33].descriptor_ui | D016219 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | methods |
| mesh[33].descriptor_name | Immunotherapy, Adoptive |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D003362 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Cost-Benefit Analysis |
| mesh[35].qualifier_ui | Q000191 |
| mesh[35].descriptor_ui | D018033 |
| mesh[35].is_major_topic | True |
| mesh[35].qualifier_name | economics |
| mesh[35].descriptor_name | Antibodies, Bispecific |
| mesh[36].qualifier_ui | Q000627 |
| mesh[36].descriptor_ui | D018033 |
| mesh[36].is_major_topic | True |
| mesh[36].qualifier_name | therapeutic use |
| mesh[36].descriptor_name | Antibodies, Bispecific |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D000076962 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Receptors, Chimeric Antigen |
| mesh[38].qualifier_ui | Q000628 |
| mesh[38].descriptor_ui | D009364 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | therapy |
| mesh[38].descriptor_name | Neoplasm Recurrence, Local |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D001688 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Biological Products |
| mesh[40].qualifier_ui | Q000191 |
| mesh[40].descriptor_ui | D001688 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | economics |
| mesh[40].descriptor_name | Biological Products |
| mesh[41].qualifier_ui | Q000706 |
| mesh[41].descriptor_ui | D017048 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | statistics & numerical data |
| mesh[41].descriptor_name | Health Care Costs |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D006801 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Humans |
| mesh[43].qualifier_ui | Q000628 |
| mesh[43].descriptor_ui | D016403 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | therapy |
| mesh[43].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[44].qualifier_ui | Q000191 |
| mesh[44].descriptor_ui | D016403 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | economics |
| mesh[44].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[45].qualifier_ui | Q000188 |
| mesh[45].descriptor_ui | D016403 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | drug therapy |
| mesh[45].descriptor_name | Lymphoma, Large B-Cell, Diffuse |
| mesh[46].qualifier_ui | Q000191 |
| mesh[46].descriptor_ui | D016219 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | economics |
| mesh[46].descriptor_name | Immunotherapy, Adoptive |
| mesh[47].qualifier_ui | Q000379 |
| mesh[47].descriptor_ui | D016219 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | methods |
| mesh[47].descriptor_name | Immunotherapy, Adoptive |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D003362 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | Cost-Benefit Analysis |
| mesh[49].qualifier_ui | Q000191 |
| mesh[49].descriptor_ui | D018033 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | economics |
| mesh[49].descriptor_name | Antibodies, Bispecific |
| type | article |
| title | Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective |
| biblio.issue | 29 |
| biblio.volume | 20 |
| biblio.last_page | 2201 |
| biblio.first_page | 2189 |
| grants[0].funder | https://openalex.org/F4320309117 |
| grants[0].award_id | |
| grants[0].funder_display_name | AbbVie |
| topics[0].id | https://openalex.org/T11491 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | CAR-T cell therapy research |
| topics[1].id | https://openalex.org/T12255 |
| topics[1].field.id | https://openalex.org/fields/24 |
| topics[1].field.display_name | Immunology and Microbiology |
| topics[1].score | 0.992900013923645 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2403 |
| topics[1].subfield.display_name | Immunology |
| topics[1].display_name | Biosimilars and Bioanalytical Methods |
| topics[2].id | https://openalex.org/T10185 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.989300012588501 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2734 |
| topics[2].subfield.display_name | Pathology and Forensic Medicine |
| topics[2].display_name | Lymphoma Diagnosis and Treatment |
| funders[0].id | https://openalex.org/F4320309117 |
| funders[0].ror | https://ror.org/02g5p4n58 |
| funders[0].display_name | AbbVie |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8108100295066833 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C182299520 |
| concepts[1].level | 2 |
| concepts[1].score | 0.5127192735671997 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1289588 |
| concepts[1].display_name | Total cost |
| concepts[2].id | https://openalex.org/C2779974597 |
| concepts[2].level | 2 |
| concepts[2].score | 0.4969487488269806 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q28448986 |
| concepts[2].display_name | Clinical Practice |
| concepts[3].id | https://openalex.org/C142424586 |
| concepts[3].level | 2 |
| concepts[3].score | 0.46839165687561035 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q7307572 |
| concepts[3].display_name | Refractory (planetary science) |
| concepts[4].id | https://openalex.org/C12713177 |
| concepts[4].level | 2 |
| concepts[4].score | 0.4647829532623291 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1900281 |
| concepts[4].display_name | Perspective (graphical) |
| concepts[5].id | https://openalex.org/C2779338263 |
| concepts[5].level | 2 |
| concepts[5].score | 0.4623922109603882 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q208414 |
| concepts[5].display_name | Lymphoma |
| concepts[6].id | https://openalex.org/C11644782 |
| concepts[6].level | 2 |
| concepts[6].score | 0.4578913152217865 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q15401790 |
| concepts[6].display_name | Cost efficiency |
| concepts[7].id | https://openalex.org/C127454912 |
| concepts[7].level | 2 |
| concepts[7].score | 0.41485950350761414 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q942582 |
| concepts[7].display_name | Cost–benefit analysis |
| concepts[8].id | https://openalex.org/C143998085 |
| concepts[8].level | 1 |
| concepts[8].score | 0.3377116322517395 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[8].display_name | Oncology |
| concepts[9].id | https://openalex.org/C126322002 |
| concepts[9].level | 1 |
| concepts[9].score | 0.32293081283569336 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[9].display_name | Internal medicine |
| concepts[10].id | https://openalex.org/C512399662 |
| concepts[10].level | 1 |
| concepts[10].score | 0.2230289876461029 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q3505712 |
| concepts[10].display_name | Family medicine |
| concepts[11].id | https://openalex.org/C121955636 |
| concepts[11].level | 1 |
| concepts[11].score | 0.10733726620674133 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q4116214 |
| concepts[11].display_name | Accounting |
| concepts[12].id | https://openalex.org/C41008148 |
| concepts[12].level | 0 |
| concepts[12].score | 0.09606853127479553 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q21198 |
| concepts[12].display_name | Computer science |
| concepts[13].id | https://openalex.org/C144133560 |
| concepts[13].level | 0 |
| concepts[13].score | 0.07593652606010437 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q4830453 |
| concepts[13].display_name | Business |
| concepts[14].id | https://openalex.org/C18903297 |
| concepts[14].level | 1 |
| concepts[14].score | 0.0 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q7150 |
| concepts[14].display_name | Ecology |
| concepts[15].id | https://openalex.org/C87355193 |
| concepts[15].level | 1 |
| concepts[15].score | 0.0 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q411 |
| concepts[15].display_name | Astrobiology |
| concepts[16].id | https://openalex.org/C121332964 |
| concepts[16].level | 0 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q413 |
| concepts[16].display_name | Physics |
| concepts[17].id | https://openalex.org/C86803240 |
| concepts[17].level | 0 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[17].display_name | Biology |
| concepts[18].id | https://openalex.org/C154945302 |
| concepts[18].level | 1 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q11660 |
| concepts[18].display_name | Artificial intelligence |
| concepts[19].id | https://openalex.org/C111919701 |
| concepts[19].level | 1 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q9135 |
| concepts[19].display_name | Operating system |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8108100295066833 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/total-cost |
| keywords[1].score | 0.5127192735671997 |
| keywords[1].display_name | Total cost |
| keywords[2].id | https://openalex.org/keywords/clinical-practice |
| keywords[2].score | 0.4969487488269806 |
| keywords[2].display_name | Clinical Practice |
| keywords[3].id | https://openalex.org/keywords/refractory |
| keywords[3].score | 0.46839165687561035 |
| keywords[3].display_name | Refractory (planetary science) |
| keywords[4].id | https://openalex.org/keywords/perspective |
| keywords[4].score | 0.4647829532623291 |
| keywords[4].display_name | Perspective (graphical) |
| keywords[5].id | https://openalex.org/keywords/lymphoma |
| keywords[5].score | 0.4623922109603882 |
| keywords[5].display_name | Lymphoma |
| keywords[6].id | https://openalex.org/keywords/cost-efficiency |
| keywords[6].score | 0.4578913152217865 |
| keywords[6].display_name | Cost efficiency |
| keywords[7].id | https://openalex.org/keywords/cost–benefit-analysis |
| keywords[7].score | 0.41485950350761414 |
| keywords[7].display_name | Cost–benefit analysis |
| keywords[8].id | https://openalex.org/keywords/oncology |
| keywords[8].score | 0.3377116322517395 |
| keywords[8].display_name | Oncology |
| keywords[9].id | https://openalex.org/keywords/internal-medicine |
| keywords[9].score | 0.32293081283569336 |
| keywords[9].display_name | Internal medicine |
| keywords[10].id | https://openalex.org/keywords/family-medicine |
| keywords[10].score | 0.2230289876461029 |
| keywords[10].display_name | Family medicine |
| keywords[11].id | https://openalex.org/keywords/accounting |
| keywords[11].score | 0.10733726620674133 |
| keywords[11].display_name | Accounting |
| keywords[12].id | https://openalex.org/keywords/computer-science |
| keywords[12].score | 0.09606853127479553 |
| keywords[12].display_name | Computer science |
| keywords[13].id | https://openalex.org/keywords/business |
| keywords[13].score | 0.07593652606010437 |
| keywords[13].display_name | Business |
| language | en |
| locations[0].id | doi:10.1080/14796694.2024.2354157 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S174572715 |
| locations[0].source.issn | 1479-6694, 1744-8301 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1479-6694 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Future Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310321119 |
| locations[0].source.host_organization_name | Future Medicine |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310321119 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Future Oncology |
| locations[0].landing_page_url | https://doi.org/10.1080/14796694.2024.2354157 |
| locations[1].id | pmid:38913826 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Future oncology (London, England) |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38913826 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11508956 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | acceptedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | True |
| locations[2].is_published | False |
| locations[2].raw_source_name | Future Oncol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11508956 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5042921399 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5348-6065 |
| authorships[0].author.display_name | Matthew Lei |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210087915 |
| authorships[0].affiliations[0].raw_affiliation_string | Pharmacy Department, Massachusetts General Hospital, Boston, MA 02114, USA |
| authorships[0].institutions[0].id | https://openalex.org/I4210087915 |
| authorships[0].institutions[0].ror | https://ror.org/002pd6e78 |
| authorships[0].institutions[0].type | healthcare |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210087915, https://openalex.org/I48633490 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Massachusetts General Hospital |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Matthew Lei |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Pharmacy Department, Massachusetts General Hospital, Boston, MA 02114, USA |
| authorships[1].author.id | https://openalex.org/A5048702334 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Qianyi Li |
| authorships[1].affiliations[0].raw_affiliation_string | Market Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Qianyi Li |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Market Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA |
| authorships[2].author.id | https://openalex.org/A5079071713 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Ken O’Day |
| authorships[2].affiliations[0].raw_affiliation_string | Market Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Ken O'Day |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Market Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA |
| authorships[3].author.id | https://openalex.org/A5052712607 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Kellie Meyer |
| authorships[3].affiliations[0].raw_affiliation_string | Market Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Kellie Meyer |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Market Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA |
| authorships[4].author.id | https://openalex.org/A5007192173 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-9509-6257 |
| authorships[4].author.display_name | Anthony Wang |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I2948539688 |
| authorships[4].affiliations[0].raw_affiliation_string | Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL 60064, USA |
| authorships[4].institutions[0].id | https://openalex.org/I2948539688 |
| authorships[4].institutions[0].ror | https://ror.org/02g5p4n58 |
| authorships[4].institutions[0].type | company |
| authorships[4].institutions[0].lineage | https://openalex.org/I2948539688 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | AbbVie (United States) |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Anthony Wang |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Health Economics and Outcomes Research, AbbVie Inc., North Chicago, IL 60064, USA |
| authorships[5].author.id | https://openalex.org/A5052085610 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Monika Jun |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I266595603 |
| authorships[5].affiliations[0].raw_affiliation_string | Center for Outcomes Research, Real-world Evidence and Epidemiology, Genmab US, Inc., Plainsboro, NJ 08536, USA |
| authorships[5].institutions[0].id | https://openalex.org/I266595603 |
| authorships[5].institutions[0].ror | https://ror.org/05258cy55 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I266595603, https://openalex.org/I4210163256 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Genmab (United States) |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Monika P Jun |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Center for Outcomes Research, Real-world Evidence and Epidemiology, Genmab US, Inc., Plainsboro, NJ 08536, USA |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11508956 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11491 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | CAR-T cell therapy research |
| related_works | https://openalex.org/W2883338879, https://openalex.org/W2377321712, https://openalex.org/W2059247764, https://openalex.org/W2355800873, https://openalex.org/W2356481580, https://openalex.org/W2320848842, https://openalex.org/W397034128, https://openalex.org/W2064948159, https://openalex.org/W2011252389, https://openalex.org/W237763381 |
| cited_by_count | 0 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:11508956 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | other-oa |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | https://openalex.org/licenses/other-oa |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Future Oncol |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11508956 |
| primary_location.id | doi:10.1080/14796694.2024.2354157 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S174572715 |
| primary_location.source.issn | 1479-6694, 1744-8301 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1479-6694 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Future Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310321119 |
| primary_location.source.host_organization_name | Future Medicine |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310321119 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Future Oncology |
| primary_location.landing_page_url | https://doi.org/10.1080/14796694.2024.2354157 |
| publication_date | 2024-06-24 |
| publication_year | 2024 |
| referenced_works | https://openalex.org/W2518731208, https://openalex.org/W2744261860, https://openalex.org/W3134205746, https://openalex.org/W4224278382, https://openalex.org/W4316926481, https://openalex.org/W2966881177, https://openalex.org/W3201485532, https://openalex.org/W4293253058, https://openalex.org/W4360601141, https://openalex.org/W2759513216, https://openalex.org/W2169183166, https://openalex.org/W4220862006, https://openalex.org/W3139382474, https://openalex.org/W1989471045, https://openalex.org/W1997974920, https://openalex.org/W4206994123, https://openalex.org/W1997514259, https://openalex.org/W1988149797, https://openalex.org/W2117922713, https://openalex.org/W2472310215, https://openalex.org/W2074831318, https://openalex.org/W3169026628, https://openalex.org/W4205438697, https://openalex.org/W2007514736, https://openalex.org/W3005440288, https://openalex.org/W3146983201, https://openalex.org/W2997486154, https://openalex.org/W3001762024, https://openalex.org/W2151887932, https://openalex.org/W4389219761, https://openalex.org/W4389235065, https://openalex.org/W4391602474 |
| referenced_works_count | 32 |
| abstract_inverted_index.1 | 65 |
| abstract_inverted_index.a | 87, 109 |
| abstract_inverted_index.An | 24 |
| abstract_inverted_index.of | 37, 46 |
| abstract_inverted_index.on | 86, 108 |
| abstract_inverted_index.to | 84, 106 |
| abstract_inverted_index.vs | 48, 78, 100 |
| abstract_inverted_index.all | 72 |
| abstract_inverted_index.and | 16, 34, 44, 50, 60, 80, 93, 102 |
| abstract_inverted_index.are | 18 |
| abstract_inverted_index.for | 4, 20, 31 |
| abstract_inverted_index.had | 81, 103 |
| abstract_inverted_index.the | 57 |
| abstract_inverted_index.was | 29, 76, 98 |
| abstract_inverted_index.cost | 17, 27 |
| abstract_inverted_index.over | 64 |
| abstract_inverted_index.time | 39, 73 |
| abstract_inverted_index.year | 66 |
| abstract_inverted_index.Novel | 1 |
| abstract_inverted_index.chair | 61, 69, 94 |
| abstract_inverted_index.costs | 45, 83, 105 |
| abstract_inverted_index.large | 7 |
| abstract_inverted_index.model | 28 |
| abstract_inverted_index.time, | 62 |
| abstract_inverted_index.time. | 95 |
| abstract_inverted_index.1-year | 33 |
| abstract_inverted_index.Across | 71 |
| abstract_inverted_index.B-cell | 8 |
| abstract_inverted_index.T-cell | 11 |
| abstract_inverted_index.basis. | 111 |
| abstract_inverted_index.cycles | 36 |
| abstract_inverted_index.except | 63 |
| abstract_inverted_index.median | 35 |
| abstract_inverted_index.time). | 70 |
| abstract_inverted_index.(second | 67 |
| abstract_inverted_index.axi-cel | 79, 101 |
| abstract_inverted_index.diffuse | 6 |
| abstract_inverted_index.include | 10 |
| abstract_inverted_index.options | 3 |
| abstract_inverted_index.reduced | 91 |
| abstract_inverted_index.similar | 82, 104 |
| abstract_inverted_index.6-month, | 32 |
| abstract_inverted_index.Overall, | 54 |
| abstract_inverted_index.Practice | 14 |
| abstract_inverted_index.horizons | 40 |
| abstract_inverted_index.informed | 21 |
| abstract_inverted_index.lymphoma | 9 |
| abstract_inverted_index.practice | 42 |
| abstract_inverted_index.required | 56 |
| abstract_inverted_index.shortest | 58, 68 |
| abstract_inverted_index.comparing | 41 |
| abstract_inverted_index.developed | 30 |
| abstract_inverted_index.horizons, | 74 |
| abstract_inverted_index.important | 19 |
| abstract_inverted_index.per-month | 88, 110 |
| abstract_inverted_index.personnel | 59, 92 |
| abstract_inverted_index.targeting | 12 |
| abstract_inverted_index.treatment | 2, 22, 38 |
| abstract_inverted_index.ciloleucel | 52 |
| abstract_inverted_index.efficiency | 15, 43 |
| abstract_inverted_index.glofitamab | 49, 85, 107 |
| abstract_inverted_index.therapies. | 13 |
| abstract_inverted_index.<b>Aim:</b> | 0 |
| abstract_inverted_index.Epcoritamab | 90 |
| abstract_inverted_index.cost-saving | 77, 99 |
| abstract_inverted_index.epcoritamab | 47, 55, 75, 97 |
| abstract_inverted_index.axicabtagene | 51 |
| abstract_inverted_index.Additionally, | 96 |
| abstract_inverted_index.institutional | 25 |
| abstract_inverted_index.decision-maker | 26 |
| abstract_inverted_index.relapsed/refractory | 5 |
| abstract_inverted_index.basis.<b>Conclusion:</b> | 89 |
| abstract_inverted_index.(axi-cel).<b>Results:</b> | 53 |
| abstract_inverted_index.decisions.<b>Materials/methods:</b> | 23 |
| cited_by_percentile_year | |
| corresponding_author_ids | https://openalex.org/A5048702334 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 6 |
| citation_normalized_percentile.value | 0.1941785 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |